Najnowsze wersje próbne


EudraCT Number: 2017-002961-23 Sponsor Protocol Number: ODO-TE-B301 Start Date:
Sponsor Name: Odonate Therapeutics, Inc.
Full Title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally...
Medical condition: Patients with Breast Cancer
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: CZ (Prematurely Ended) HU (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2008-000640-14 Sponsor Protocol Number: 1245.9 Start Date:
Sponsor Name: Boehringer ingelheim Pharma GmbH & Co KG
Full Title: A Phase IIb, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (5mg, 10mg and 25mg) administered orally once daily over 12 weeks compared double blind to placebo, ...
Medical condition: Type 2 Diabetes mellitus
Disease: Version SOC Term Classification Code Term Level
9.1 10045242 Type II diabetes mellitus LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed) SE (Completed) IT (Completed) EE (Completed) LT (Completed) SK (Completed)
Trial results: View results
EudraCT Number: 2022-002367-29 Sponsor Protocol Number: ITM202203 Start Date:
Sponsor Name: Instituut van Tropische Geneeskunde Antwerpen
Full Title: A two-centre open-label non-inferiority trial to assess the immunogenicity and safety of an intradermal and an intramuscular single-visit dosing regimen of purified chick-embryo cell-culture rabies...
Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli...
Disease: Version SOC Term Classification Code Term Level
20.0 10021881 - Infections and infestations 10037742 Rabies PT
Population Age: Adults Gender: Male, Female
Trial protocol: BE (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2018-000261-36 Sponsor Protocol Number: HTA-HG5-02 Start Date:
Sponsor Name: HOLOSTEM TERAPIE AVANZATE S.R.L.
Full Title: MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED ...
Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient's qu...
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: IT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2013-002896-17 Sponsor Protocol Number: V1.17.05.2013 Start Date:
Sponsor Name: Orthopädisches Spital Speising
Full Title: Functional evaluation of two therapy concepts: dynamic orthoses and BoNT
Medical condition: Infantile cerebral palsy
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Under 18 Gender: Male, Female
Trial protocol: AT (Completed)
Trial results: (No results available)

EudraCT Number: 2009-012667-34 Sponsor Protocol Number: BRONCHIOLITIS Start Date:
Sponsor Name: Oslo University Hospital - Ullevål
Full Title: BRONCHIOLITIS, OPTIMAL TREATMENT IN INFANTS AND PROGNOSIS
Medical condition: Acute bronchiolitis
Disease: Version SOC Term Classification Code Term Level
12.0 10000686 Acute bronchiolitis LLT
Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
Trial protocol: NO (Ongoing)
Trial results: (No results available)
EudraCT Number: 2006-006816-31 Sponsor Protocol Number: P060104 Start Date:
Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Full Title: Effet du mazindol sur le Trouble Déficit de l'Attention/Hyperactivité chez l'enfant : étude prospective pilote (phase II) d'efficacité, de tolérance et de pharmacocinétique
Medical condition: Enfants de 6 à 12 ans présentant un TDAH et suivi dans le Service de Psychopathologie de l'Enfant et de l'Adolescent de l'Hôpital Robert Debré
Disease: Version SOC Term Classification Code Term Level
8.1 10003736 Trouble Déficit de l'Attention/Hyperactivité PT
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: FR (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-004039-10 Sponsor Protocol Number: NL78130.041.21 Start Date:
Sponsor Name: UMC Utrecht - Van Creveldkliniek
Full Title: Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study
Medical condition: Congenital hemophilia A
Disease: Version SOC Term Classification Code Term Level
20.0 100000004850 10060612 Hemophilia A LLT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2007-000440-27 Sponsor Protocol Number: 690701 Start Date:
Sponsor Name: Baxter AG
Full Title: OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMM...
Medical condition: In this Study the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies after the First Booster and the Response to a Second Booster Vaccination with FSME-IMMUN 0.5ml in Adults will be ...
Disease: Version SOC Term Classification Code Term Level
9.1 10043847 Tick-borne viral encephalitis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PL (Completed)
Trial results: View results

EudraCT Number: 2010-019550-40 Sponsor Protocol Number: AMAG-FER-CKD-253 Start Date:
Sponsor Name: AMAG Pharmaceuticals, Inc.
Full Title: An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease
Medical condition: Chronic Kidney Disease
Disease: Version SOC Term Classification Code Term Level
17.0 100000004857 10064848 Chronic kidney disease LLT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: DE (Completed) GB (Prematurely Ended) HU (Completed) ES (Completed) RO (Temporarily Halted) LT (Prematurely Ended) BG (Prematurely Ended)
Trial results: View results
3
Subskrybuj